FOLR1 and neoplasm: A major focus of ACT-based modalities hinges on successful target identification, which includes in OC MUC 16, FRα, B7H3, mesothelin, and TAG72 (130), to name a few, as well as strategies to overcome inherent limitations of antitumor T cell responses, including lack of T cell persistence, tumor heterogeneity, loss of functionality, and impaired trafficking towards the TME, all of which may benefit from the presence of TLS.